News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Questions Genzyme Corporation Knee Pain Treatment Study
December 5, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Dec 5 (Reuters) - A study of Genzyme Corp's latest version of its injectable knee pain treatment may not be strong enough to support the therapy, U.S. regulatory reviewers said in an analysis released on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Drug Development
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart
October 8, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
October 8, 2026
·
2 min read
·
Gabrielle Masson
Weight loss
Despite Zealand asset’s ‘intriguing’ weight loss, analysts underwhelmed by blood sugar numbers
October 8, 2026
·
4 min read
·
Annalee Armstrong
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
